NGI becomes first certified core lab and service provider for Epigenica’s EpiFinder platforms
Partnership expands access to high‑throughput epigenomic profiling for biomarker discovery and research applications
1 Jun 2026Industry news
Epigenica AB has entered into an agreement with the National Genomics Infrastructure (NGI), one of the largest technical platforms at SciLifeLab in Stockholm, Sweden. Under this agreement, NGI Stockholm becomes the first official core laboratory and service provider worldwide to offer Epigenica’s EpiFinder™ platform, expanding access to high-throughput, multiplex epigenomic profiling for researchers across academia, biopharma and pharmaceutical research.
Partnership expands access to high-throughput epigenomic profiling
As the first certified service provider, NGI will deliver end-to-end workflows using both EpiFinder™ cNuc, for histone and DNA methylation profiling of circulating nucleosomes in liquid biopsies, and EpiFinder GenomePro, for histone and DNA methylation profiling in cells and tissues. These platforms enable scalable, reproducible and highly robust epigenomic insights for projects of any size.
Comprehensive epigenomic services for diverse sample types
Through this collaboration, NGI users will gain access to EpiFinder cNUC and EpiFinder GenomePro platforms providing multiplexed epigenomic profiling across plasma, serum, cells and tissues. This enables powerful biomarker discovery through detailed epigenetic signatures.
Researchers will also benefit from full project support, including study design consultation, sample preparation, sequencing and downstream analysis, helping to ensure high-quality, interpretable epigenomic data.
“We are thrilled to be the first core facility certified to deliver Epigenica’s EpiFinder technologies,” said Anja Mezger, Head of Unit at NGI in Stockholm. “These platforms fill critical needs for researchers seeking high resolution epigenomic insights through streamlined workflows. With EpiFinder GenomePro and cNuc, we can offer even greater depth and capability within our service portfolio.”
Building a global network of certified epigenomic service providers
The collaboration between Epigenica and NGI is part of Epigenica’s broader strategy to establish a global network of dedicated certified service providers delivering harmonized, high-quality epigenomic data. Additional partner sites will be announced as adoption of EpiFinder GenomePro and cNuc expands across academic, biopharma and pharmaceutical research environments.
“Partnering with NGI marks the first step in scaling access to our epigenomic platforms,” said Mohamad Takwa, CEO of Epigenica. “By working with one of Europe’s leading genomics infrastructures, we are not only expanding availability of EpiFinder™ GenomePro and EpiFinder™ cNUC, but also establishing a model for how these technologies can be deployed more broadly. This collaboration lays the foundation for a growing network of partners and will support more consistent, high-quality epigenomic research at scale.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does the Epigenica–NGI partnership expand global access to high-throughput epigenomic profiling?
Under the agreement, the National Genomics Infrastructure (NGI) in Stockholm becomes the first official core laboratory and certified service provider worldwide to offer Epigenica’s EpiFinder™ platform.
NGI will deliver end-to-end workflows using EpiFinder™ cNuc for histone and DNA methylation profiling of circulating nucleosomes in liquid biopsies, and EpiFinder GenomePro for histone and DNA methylation profiling in cells and tissues. This partnership expands access to scalable, reproducible and robust high-throughput multiplex epigenomic profiling for researchers across academia, biopharma and pharmaceutical research, and serves as a model for building a broader global network of certified epigenomic service providers.
What epigenomic services do EpiFinder cNuc and EpiFinder GenomePro provide for biomarker discovery in plasma, serum, cells and tissues?
Through the collaboration between Epigenica AB and NGI Stockholm, users gain access to EpiFinder cNuc and EpiFinder GenomePro platforms that enable multiplexed epigenomic profiling across plasma, serum, cells and tissues. These platforms support histone and DNA methylation profiling of circulating nucleosomes in liquid biopsies as well as in cells and tissues, generating detailed epigenetic signatures. This comprehensive coverage enables powerful biomarker discovery and high-resolution epigenomic insights for projects of any size.
How will Epigenica’s EpiFinder platform and NGI’s certified core facility support high-quality epigenomic research for academia, biopharma and pharmaceutical sectors?
As the first certified service provider for Epigenica’s EpiFinder technologies, NGI offers full project support, including study design consultation, sample preparation, sequencing and downstream analysis.
By combining EpiFinder GenomePro and EpiFinder cNuc with NGI’s established genomics infrastructure, researchers in academic, biopharma and pharmaceutical environments gain access to streamlined workflows, harmonized high-quality epigenomic data and consistent, interpretable results. This collaboration lays the foundation for a growing global network of certified service providers dedicated to delivering robust epigenomic research at scale.